Background: Type-2 Diabetes is a long lasting disease characterized by high glucose concentration in
the blood due to insulin resistance. One of the recent treatment strategies is using activators against SIRT-1,
which has been in clinical trials. Hence, it is necessary to know the effects of the SIRT-1 modulators against
various metabolic pathways.
Methods: Many cellular processes, including insulin secretion, cell cycle, and apoptosis are imperatively regulated
by a family of mediators called SIRTuins. First known mammalian sirtuin, SIRT1 is a positive regulator of
insulin secretion, which triggers glucose uptake and utilization. For the past decade, a major outstanding question
is whether SIRT1 activation is a safe therapy for human diseases such as diabetes?
Results: This review summarizes and discusses the advances of the past decade and the challenges that will brazen
out perplexity of this field. We also cover the physiological regulation of sirtuin (SIRT1) activity and how
these modes of regulation may be exploited to manipulate SIRT1 activity in cells. Designing of drugs using advanced
computational methods that specifically target SIRT1, and also, involvement of advanced biological
methods for further understanding of sirtuin1 biology to afford new optimized treatments for diabetes and several
age related human diseases.
Conclusion: Hence, this review is a serial perspective of all the above topics.